Suppr超能文献

The Impact of CED On Private Payers.

作者信息

Atkinson William

出版信息

Biotechnol Healthc. 2007 Apr;4(2):24-30.

Abstract

Is 'coverage with evidence development' a happy medium between 'no evidence, no coverage,' and the sky-high promise of some new biologic therapies, diagnostics, and devices? Medicare plans to find out. The application of CED raises a number of questions, the answers to which may determine whether it is a suitable model for private payers trying to answer the value equation.

摘要

相似文献

1
The Impact of CED On Private Payers.
Biotechnol Healthc. 2007 Apr;4(2):24-30.
3
Coverage options for promising technologies: Medicare's 'coverage with evidence development'.
Health Aff (Millwood). 2006 Sep-Oct;25(5):1218-30. doi: 10.1377/hlthaff.25.5.1218.
4
Private payers disagree with Medicare over medical device coverage about half the time.
Health Aff (Millwood). 2015 Aug;34(8):1376-82. doi: 10.1377/hlthaff.2015.0133.
5
Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.
Health Aff (Millwood). 2006 Sep-Oct;25(5):1231-9. doi: 10.1377/hlthaff.25.5.1231.
6
Multiple payers, commonality and free-riding in health care: Medicare and private payers.
J Health Econ. 2002 Nov;21(6):1049-69. doi: 10.1016/s0167-6296(02)00078-4.
7
Access with evidence development: the US experience.
Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000.
8
Coverage with Evidence Development: applications and issues.
Int J Technol Assess Health Care. 2010 Jan;26(1):79-85. doi: 10.1017/S0266462309990882.
10
Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
J Pers Med. 2018 May 16;8(2):19. doi: 10.3390/jpm8020019.

引用本文的文献

1
Overhauling the reimbursement system for molecular diagnostics.
Nat Biotechnol. 2011 May;29(5):390-1. doi: 10.1038/nbt.1869.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验